L500-1221 Screening compound: 1-{[4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)thiophen-2-yl]sulfonyl}-N-cyclopentylpiperidine-4-carboxamide

L500-1221 Screening compound: 1-{[4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)thiophen-2-yl]sulfonyl}-N-cyclopentylpiperidine-4-carboxamide
L500-1221 Screening compound: 1-{[4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)thiophen-2-yl]sulfonyl}-N-cyclopentylpiperidine-4-carboxamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L500-1221
1-{[4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)thiophen-2-yl]sulfonyl}-N-cyclopentylpiperidine-4-carboxamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L500-1221

Molecular Formula

C21H28N4O4S2 (C21 H28 N4 O4 S2)

Compound Name

1-{[4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)thiophen-2-yl]sulfonyl}-N-cyclopentylpiperidine-4-carboxamide

IUPAC name

1-{[4-(5-cyclobutyl-124-oxadiazol-3-yl)thiophen-2-yl]sulfonyl}-N-cyclopentylpiperidine-4-carboxamide

SMILES

O=C(C(CC1)CCN1S(c1cc(-c2noc(C3CCC3)n2)cs1)(=O)=O)NC1CCCC1

InChI

InChI=1S/C21H28N4O4S2/c26-20(22-17-6-1-2-7-17)14-8-10-25(11-9-14)31(27,28)18-12-16(13-30-18)19-23-21(29-24-19)15-4-3-5-15/h12-15,17H,1-11H2,(H,22,26)

InChI Key

RPPRCDQTPLIIAB-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27458579

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

464.61

Hydrogen Bond Acceptors Count

10.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

7.00

Number of Nitrogen and Oxygen Atoms

8

Partition Coefficient, logP

3.441

Distribution Coefficient, logD

3.441

Water Solubility, LogSw

-3.65

Polar Surface Area

89.401

Acid Dissociation Constant (pKa)

15.70

Base Dissociation Constant (pKb)

5.67

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

66.70

L500-1221 in Drug Discovery

Included in Screening Libraries

3D-Pharmacophore Based Diversity Library (49813 compounds)

GPCR Targeted Library (31838 compounds)

Macl-GPIb alpha Interaction Library (22969 compounds)

PPI Inhibitors Tripeptide Mimetics (23972 compounds)

Peptidomimetic Library (37031 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Musculoskeletal
  • Respiratory tract
  • Nervous system
  • Congenital
  • Skin
  • Metabolic
  • Endocrine
  • Hemic and lymphatic
  • Cardiovascular
Targets:
  • GPCR
Mechanism of action:
  • Receptor's ligands
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics
  • Mimetics

References: we are preparing a list of scientific research reports with L500-1221 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L500-1221?
Check Price and Availability of L500-1221, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L500-1221 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L500-1221
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L500-1221
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L500-1221 available by request